1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Al001: new trials by email Literature Review of Al001 trials Research Report on Al001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuation Study for Latozinemab Latozinemab - Neurodegenerative Diseases | Phase 3 | Terminated | Alector Inc. | 17 | 2023-12-08 | 2026-01-21 |
Amyotrophic Lateral Sclerosis (1) · Frontotemporal Dementia (1) · Neurodegenerative Diseases (1)
Alector Inc. (1)
Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Portugal (1) · Sweden (1) · United Kingdom (1) · United States (1)
2023 (1)